Autolus Therapeutics (AUTL) announces that the New England Journal of Medicine has published data from the pivotal Phase 1b/2 FELIX study of ...
High overall response rate: 76.6% of patients in the pivotal cohort achieved CR/Cri following treatment with obe-cel with a median follow-up of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback